OBJECTIVES To critically assess the prevalence among schoolchildren 6 to 9 years of age throughout the Dominican Republic of a bacille Calmette-Guérin (BCG) vaccination scar, and to examine the relationship between nutritional and sociodemographic factors and the likelihood of having a BCG scar. METHODS This correlational study used the database of the Second National Census on Height and Wei...

Intravesical Mycobacterium bovis BCG instillation therapy is commonly used to prevent recurrences of carcinoma in situ (CIS) and/or Ta/T1 papillary tumors of the urinary bladder (8). A rare and serious complication associated with BCG treatment of bladder cancer is the development of disseminated BCG disease (1, 6). Current recommendations for bladder cancer patients (being treated with BCG) wh...

Non-muscle invasive bladder cancer (NMIBC) is a common urological malignancy, and bacillus Calmette-Guérin (BCG) therapy the gold standard treatment in intermediate high-risk groups. However, BCG failure occurs significant proportion of patients, emphasizing need for effective alternative modalities to address this burden. These treatments include immunotherapy, enhanced drug delivery, targeted...

Abstract In recent decades ballistocardiography (BCG) has regained popularity as a way to measure the mechanical activ- ity of heart. this paper we present and evaluate new iteration our mobile BCG measurement system. The pro- posed system uses an inertial unit (IMU) placed on carotid artery derive BCG. We conducted mea- surement series do initial in- vestigation into whether more complex heart...

Intravesical Bacillus Calmette Guerin (BCG) immunotherapy is the standard initial therapy for patients with high-grade urothelial bladder cancer without muscle invasion. While minor complications due to intravesical BCG immunotherapy are common, cutaneous infections of the glans penis are quite rare. Granulomatous balanitis can be devastating if not identified and treated early. A well-establis...

A prime-boost strategy conserving BCG is considered the most promising vaccine to control tuberculosis. A boost with a DNA vaccine containing the mycobacterial gene of a heat shock protein (pVAXhsp65) after BCG priming protected mice against experimental tuberculosis. However, anti-hsp65 immunity could worsen an autoimmune disease due to molecular mimicry. In this investigation, we evaluated th...

The only tuberculosis vaccine currently available, bacille Calmette-Guérin (BCG) is a poor inducer of CD8(+) T cells, which are particularly important for the control of latent tuberculosis and protection against reactivation. As the induction of strong CD8(+) T cell responses is a hallmark of DNA vaccines, a combination of BCG with plasmid DNA encoding a prototype TB antigen (Ag85A) was tested...

This paper provides recommendations on the management of complications arising from intravesical treatment with bacillus Calmette-Guérin (BCG) for nonmuscle-invasive bladder tumors. There is minimal recommendations currently available as randomized trials on the side effects of intravesical BCG are lacking and severe complications are usually described in case reports only. All physicians givin...

Purpose The short-term effects of intravesical chemoimmunotherapy with epirubicin and Bacillus CalmetteGuerin (BCG) administered repeatedlly for prophylaxis of recurrence of superficial bladder cancer (pTa, pT1) were investigated in 22 patients with a median of 70 years between March, 1995 and February, 1999, and were compared with those of BCG monotherapy in 50 patients between March, 1995 and...

Tuberculosis (TB) is one of the most important causes of mortality and morbidity due to infectious diseases. BCG, the vaccine in use, is not fully protective against TB. In a previous study, we have shown that proteoliposomes (outer membrane extracts), obtained from BCG (PLBCG) were able to induce humoral immune responses against Mycobacterium tuberculosis (Mtb) antigens. With the objective to ...